

Mohamed Ismail Abdul Aziz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8907559/publications.pdf>

Version: 2024-02-01

13
papers

139
citations

1306789

7
h-index

1281420

11
g-index

14
all docs

14
docs citations

14
times ranked

158
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. <i>Journal of Asthma</i> , 2022, 59, 189-199.	0.9	10
2	Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022, 22, 207-215.	0.7	1
3	Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore. <i>Cancer Reports</i> , 2021, 4, e1308.	0.6	7
4	Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 449-456.	0.7	11
5	Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by <i>BRCA1/2</i> mutation status for platinum-sensitive relapsed ovarian cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 441-448.	0.7	7
6	Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore. <i>Vaccine</i> , 2021, 39, 2255-2263.	1.7	5
7	Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore. <i>Journal of Medical Economics</i> , 2020, 23, 1330-1339.	1.0	11
8	Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore's healthcare system perspective. <i>Journal of Medical Economics</i> , 2020, 23, 1321-1329.	1.0	20
9	Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer. <i>Journal of Medical Economics</i> , 2020, 23, 952-960.	1.0	13
10	Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer. <i>BMC Health Services Research</i> , 2020, 20, 581.	0.9	20
11	Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore. <i>Journal of Medical Economics</i> , 2020, 23, 838-847.	1.0	7
12	Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 126-133.	0.2	11
13	Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. <i>BMC Cancer</i> , 2018, 18, 352.	1.1	16